Company news
Artelo Biosciences, Inc. news in 2025
Artelo Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
December 23, 2025
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
December 3, 2025
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
November 4, 2025
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
October 26, 2025
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
October 15, 2025
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
October 1, 2025
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
September 30, 2025
Artelo Biosciences Announces Proposed Underwritten Public Offering
September 29, 2025
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
September 29, 2025
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
September 10, 2025
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
September 5, 2025
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
September 4, 2025
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
September 3, 2025
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
September 3, 2025
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
August 25, 2025
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
August 11, 2025
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
August 3, 2025
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD: TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
August 1, 2025
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
July 9, 2025
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
July 7, 2025
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
June 30, 2025
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
June 26, 2025
Artelo Biosciences Announces Reverse Stock Split
June 11, 2025
Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
June 5, 2025
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
June 2, 2025
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
May 13, 2025
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
April 28, 2025
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
March 31, 2025
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
March 3, 2025
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
February 13, 2025
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
January 12, 2025